🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
11.17
-0.08 (-0.71%)
At close: Nov 19, 2026, 4:00 PM EST
11.19
+0.02 (0.18%)
After-hours: Nov 19, 2026, 7:30 PM EST

ImmuCell Statistics

Total Valuation

ImmuCell has a market cap or net worth of $101.45 million. The enterprise value is $105.54 million.

Market Cap101.45M
Enterprise Value 105.54M

Important Dates

The last earnings date was Thursday, November 12, 2026, after market close.

Earnings Date Nov 12, 2026
Ex-Dividend Date n/a

Share Statistics

ImmuCell has 9.08 million shares outstanding. The number of shares has increased by 1.70% in one year.

Current Share Class 9.08M
Shares Outstanding 9.08M
Shares Change (YoY) +1.70%
Shares Change (QoQ) +1.18%
Owned by Insiders (%) 28.23%
Owned by Institutions (%) 22.16%
Float 6.02M

Valuation Ratios

The trailing PE ratio is 56.82.

PE Ratio 56.82
Forward PE n/a
PS Ratio 3.10
Forward PS n/a
PB Ratio 3.12
P/TBV Ratio 3.15
P/FCF Ratio 19.08
P/OCF Ratio 13.16
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.80, with an EV/FCF ratio of 19.84.

EV / Earnings 57.02
EV / Sales 3.23
EV / EBITDA 13.80
EV / EBIT 19.13
EV / FCF 19.84

Financial Position

The company has a current ratio of 4.61, with a Debt / Equity ratio of 0.37.

Current Ratio 4.61
Quick Ratio 2.41
Debt / Equity 0.37
Debt / EBITDA 1.46
Debt / FCF 2.22
Interest Coverage 11.36

Financial Efficiency

Return on equity (ROE) is 6.01% and return on invested capital (ROIC) is 15.24%.

Return on Equity (ROE) 6.01%
Return on Assets (ROA) 7.48%
Return on Invested Capital (ROIC) 15.24%
Return on Capital Employed (ROCE) 12.95%
Weighted Average Cost of Capital (WACC) 7.27%
Revenue Per Employee $454,923
Profits Per Employee $25,748
Employee Count73
Asset Turnover 0.71
Inventory Turnover 2.00

Taxes

In the past 12 months, ImmuCell has paid $44,543 in taxes.

Income Tax 44,543
Effective Tax Rate 2.31%

Stock Price Statistics

The stock price has increased by +144.96% in the last 52 weeks. The beta is 0.62, so ImmuCell's price volatility has been lower than the market average.

Beta (5Y) 0.62
52-Week Price Change +144.96%
50-Day Moving Average 10.21
200-Day Moving Average 9.16
Relative Strength Index (RSI) 62.21
Average Volume (20 Days) 13,941

Short Selling Information

The latest short interest is 14,706, so 0.16% of the outstanding shares have been sold short.

Short Interest 14,706
Short Previous Month 18,103
Short % of Shares Out 0.16%
Short % of Float 0.24%
Short Ratio (days to cover) 1.58

Income Statement

In the last 12 months, ImmuCell had revenue of $33.21 million and earned $1.88 million in profits. Earnings per share was $0.20.

Revenue33.21M
Gross Profit 13.56M
Operating Income 5.60M
Pretax Income 1.92M
Net Income 1.88M
EBITDA 7.77M
EBIT 5.60M
Earnings Per Share (EPS) $0.20
Full Income Statement

Balance Sheet

The company has $7.91 million in cash and $12.01 million in debt, with a net cash position of -$4.10 million or -$0.45 per share.

Cash & Cash Equivalents 7.91M
Total Debt 12.01M
Net Cash -4.10M
Net Cash Per Share -$0.45
Equity (Book Value) 32.77M
Book Value Per Share 3.61
Working Capital 16.90M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $7.83 million and capital expenditures -$2.43 million, giving a free cash flow of $5.40 million.

Operating Cash Flow 7.83M
Capital Expenditures -2.43M
Depreciation & Amortization 2.16M
Net Borrowing -1.60M
Free Cash Flow 5.40M
FCF Per Share $0.59
Full Cash Flow Statement

Margins

Gross margin is 40.83%, with operating and profit margins of 16.87% and 5.66%.

Gross Margin 40.83%
Operating Margin 16.87%
Pretax Margin 5.79%
Profit Margin 5.66%
EBITDA Margin 23.39%
EBIT Margin 16.87%
FCF Margin 16.27%

Dividends & Yields

ImmuCell does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -1.70%
Shareholder Yield -1.70%
Earnings Yield 1.76%
FCF Yield 5.24%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (3Y) n/a
EPS Growth Forecast (3Y) n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 7